



A Response to: Letter to the Editor regarding “Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes”

Neil Skolnik · Alyssa Style

Received: July 8, 2021 / Accepted: July 18, 2022 / Published online: August 5, 2022
© The Author(s) 2022

Keywords: Type 2 diabetes mellitus; Chronic kidney disease; Kidney function screening

Thank you Dr. Nataraj, Dr. Maiya, and Dr. Nagaraju for your response.

Although we have focused on US guidelines surrounding chronic kidney disease (CKD) in people with type 2 diabetes mellitus, this is clearly a global issue. We recognize that the standard of care in the USA may differ from other countries. The goal of frequent kidney function screening in people with diabetes is to prevent patients from presenting with gross symptoms of CKD as in the example given.

We agree that prevention is key. We look forward to learning more about the role of exercise in CKD prevention as further research develops. The guidelines we presented and medications described to help prevent and slow progression of CKD are reliant on access to resources in the community. Unfortunately, there are many obstacles including costs, access to specialists, health literacy, and patient non-adherence. However, we must advocate for our patients to prevent the long-term consequences of CKD.

N. Skolnik (✉) · A. Style
Abington Family Medicine, Abington Jefferson
Health, Jenkintown, PA, USA
e-mail: nskolnik@comcast.net

ACKNOWLEDGEMENTS

Funding. No funding or sponsorship was received for this study or publication of this article.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Both authors participated in the drafting, critical revision, and approval of the final version of the manuscript.

Disclosures. Neil Skolnik (Advisory Boards and Consultant—AstraZeneca, Teva, Lilly, Boehringer Ingelheim, Sanofi, Sanofi Pasteur, GSK, Bayer, Genetch, Abbott, Idorsia; Speaker—AstraZeneca; Boehringer Ingelheim; Lilly, GSK, Bayer; Research Support—Sanofi, AstraZeneca, Boehringer Ingelheim, GSK, Bayer, Novo Nordisk). Alyssa Style has nothing to disclose.

Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material

in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.